Key result
Sleeve gastrectomy significantly improved cardiovascular parameters at 1 year, including HDL-cholesterol (P=0.002), intima media thickness (P=0.003), and flow-mediated dilation (P=0.001).
Why the study?
Cardiovascular and renal diseases drive morbidity and mortality in obesity and type 2 diabetes mellitus, and bariatric surgery has the potential to reverse cardiovascular, renal, and metabolic disease.
Does sleeve gastrectomy improve cardiovascular, renal, and metabolic parameters in patients with morbid obesity?
Cohort (n=24)
Does sleeve gastrectomy improve cardiovascular, renal, and metabolic parameters in patients with morbid obesity?
p-value: p=0.002 (HDL), 0.003 (IMT), <0.001 (EAT), 0.001 (FMD)
Sleeve gastrectomy significantly improves cardiovascular, renal, and metabolic surrogate markers at 1 year in patients with morbid obesity.
Associated CV surrogate improvements support further study; should not yet change practice pending RCTs.
Cardiovascular and renal diseases represent a major determinant for the morbidity and mortality associated with obesity and type 2 diabetes mellitus (T2DM). Bariatric surgery is considered one of the few treatments with the potential to reverse cardiovascular, renal and metabolic disease. Prospective study of patients undergoing sleeve gastrectomy collecting pre- and post-surgery creatinine, eGFR, glucose, insulin, total, LDL/HDL cholesterol, triglycerides, parathyroid hormone, vitamin D3, C- Reactive Protein (CRP), blood count, weight, body mass index (BMI), bilateral carotid intima media thickness (IMT), flow-mediated dilation (FMD) and epicardial adipose tissue (EAT). Measurements were compared at 1 year follow up. 24 patients were included in the study. Cardiovascular parameters, as HDL-cholesterol (p = 0.002), IMT (p = 0.003), EAT (p < 0.001) and FMD (p = 0.001) showed significant improvement after surgery. Secondary renal outcomes including Vitamin D3 (p < 0.0001), Calcium (p = 0.006), RBCs (p = 0.007), HCO3- (p = 0.05) also ameliorated as well as BMI (p < 0.001). Sleeve gastrectomy has a positive impact on cardiovascular, renal, and metabolic parameters in patients with morbid obesity suggesting it may halt the progression of these diseases even in the preclinical stage. Further research is needed to explore the long-term effects underlying these improvements.
No takes yet. Share an insight, caveat, or question.
Bellini et al. (2024) conducted a cohort in Morbid obesity (n=24). Sleeve gastrectomy vs. Pre-surgery baseline was evaluated on Cardiovascular parameters (HDL-cholesterol, IMT, EAT, FMD) (p=0.002 (HDL), 0.003 (IMT), <0.001 (EAT), 0.001 (FMD)). Sleeve gastrectomy significantly improved cardiovascular parameters at 1 year, including HDL-cholesterol (P=0.002), intima media thickness (P=0.003), and flow-mediated dilation (P=0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: